ABCC8 Gene Transient Neonatal Diabetes Mellitus Type 2 Genetic Test in UAE | 2800 AED | DHA Licensed

Executive Summary & Core Metrics

✓ Accuracy Guarantee

99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139). All data protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.

📦 Premium Logistics

VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM, minors require guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability).

🩺 Clinical Guidance

Telephonic Post-Test Clinical Guidance in result interpretation, aligned with DHA standards.

📋 Insurance

Direct Billing Verification via WhatsApp +971 54 548 8731 (English & Arabic).

Key Metrics

Price: 2,800 AED
Turnaround: 3–4 Weeks (expedited available)
Sample: Whole Blood (EDTA) or Dried Blood Spot
Method: NGS + Sanger confirmation

Test Overview & Methodology

The ABCC8 Gene Genetic Test detects pathogenic variants in the sulfonylurea receptor gene, confirming Transient Neonatal Diabetes Mellitus Type 2 — a rare monogenic diabetes presenting in the first weeks of life. This molecular assay enables precise differentiation from permanent neonatal diabetes and guides early transition from insulin to oral sulfonylurea therapy.

Feature	Our Premium Test	Closest Alternative
Precision	NGS full gene sequencing (>99% analytical sensitivity)	Targeted mutation panel (may miss rare variants)
Methodology	Illumina NovaSeq™ with Sanger confirmation	Sanger sequencing only (limited throughput)
Turnaround Time	3–4 Weeks (expedited available)	4–6 Weeks

Physician Insight & Safety Protocols

“As a consultant in medical genetics, I emphasize that this ABCC8 genetic result must be correlated with the infant’s clinical status, blood glucose, and C-peptide levels. A positive finding can guide safe transition from insulin to oral sulfonylureas, dramatically improving quality of life. Genetic counseling is recommended for family members.”

— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403

Medication Safety Advisory

⚠️ Important: Do not discontinue any prescribed medication without consulting your doctor. This genetic test is a diagnostic tool and not a therapeutic directive.

Patient Safety & Exclusion Criteria

Contraindications & Precautions

Exclusion: Inability to provide informed consent (minors require guardian consent per Federal Decree-Law No. 4 of 2016). Acute febrile illness (≥38.5°C) may postpone collection.
Red Flag Symptoms – Seek Emergency Care: Severe hyperglycemia with ketotic breathing, dehydration, or altered consciousness in the infant. This test is not for acute crisis management.
Data Privacy: All genetic data handled under Federal Decree-Law No. 45 of 2021 (PDPL); no third-party sharing without explicit consent.

Patient FAQ & Clinical Guidance

1. What exactly does the ABCC8 gene test diagnose?

This test identifies pathogenic mutations in the ABCC8 gene that cause transient neonatal diabetes mellitus type 2, enabling precise sulfonylurea therapy rather than lifelong insulin. It differentiates from permanent neonatal diabetes and other monogenic forms.

2. How is the sample collected and does it hurt my baby?

A certified pediatric phlebotomist performs a gentle heel‑prick or venipuncture under strict aseptic technique; the procedure is brief and well‑tolerated. Parents may stay present to comfort the infant.

3. Will insurance cover the ABCC8 genetic test?

Our team directly verifies your insurance eligibility and handles pre‑approval via WhatsApp; most UAE plans cover genetic testing for neonatal diabetes. Contact us for a personalized eligibility check.

4. How long does it take to get results?

Standard turnaround is 3–4 weeks from sample receipt. Expedited processing is available upon request for urgent clinical decisions. You will receive a detailed report with variant classification and clinical recommendations.

UAE Regulatory & Data Privacy Adherence

100% Compliance with UAE Law

Personal Data Protection: All genetic data is processed and stored in compliance with Federal Decree-Law No. 45 of 2021 (PDPL). No data is shared without explicit patient consent.
Health Information Technology: Our systems adhere to Federal Law No. 2 of 2019 concerning the use of ICT in health fields, ensuring secure electronic health records.
Medical Liability: Sample collection and clinical procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing patient safety and informed consent.
DHA Licensing: All testing performed under Dubai Health Authority Facility License No. 1143, with rigorous quality audits.

Clinical & Logistical Metadata

Test Name	ABCC8 Gene Transient Neonatal Diabetes Mellitus Type 2 Genetic Test
Price (AED)	2,800
Turnaround Time	3–4 Weeks (expedited available)
Sample Type / Matrix	Whole Blood (EDTA) or Dried Blood Spot
Methodology Used	NGS full gene sequencing with Sanger confirmation
ICD-10-CM Code	P70.2 (Neonatal diabetes mellitus)
LOINC Code	82237-3 (ABCC8 gene mutation analysis in Blood or Tissue by Molecular genetics method)
DHA Facility License & Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE